Could many heart patients ditch Beta-Blockers? new trial investigates

NCT ID NCT05081999

Ongoing Disease control Sponsor: University of Alberta Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether people with stable ischemic heart disease (but with normal heart pumping function and no ongoing chest pain or arrhythmias) can safely stop taking beta-blockers. About 59 participants will either continue or stop their beta-blocker and be followed for up to 4 years to compare heart events and quality of life. The goal is to see if stopping the drug reduces side effects without increasing risk.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: beta-blocker discontinuation
What this could lead to: If successful, this could show that many stable heart disease patients can safely stop taking beta-blockers, reducing side effects and medication burden.
What could go wrong: This is a small, early-phase pragmatic trial with only 59 participants, so results may not apply broadly. There is a risk that stopping beta-blockers could increase heart events.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BETA-BLOCKER THERAPY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

coronary artery disorder myocardial ischemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BETA-BLOCKER THERAPY CORONARY ARTERY DISEASE STABLE ISCHEMIC HEART DISEASE

Contacts and locations

Locations

University of Alberta Hospital

Edmonton, Alberta, T6G 2B7, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.